News | January 12, 2022
Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra
Ind-Ra expects revenue growth of over 12% in 2022.
Ind-Ra expects revenue growth of over 12% in 2022.
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
This service benefits pharmaceutical and fine chemical companies looking to optimise their reactions
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
Cobas infinity edge is designed as an open platform, allowing healthcare professionals to easily access and adopt third-party innovators’ new digital tools and medically-relevant applications via the Roche digital marketplace
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Subscribe To Our Newsletter & Stay Updated
